REVISTA DE REUMATOLOGÍA 

Referencias

 

  1. Edberg JC, Salmon JE, Kimberly RP. Systemic lupus erythematosus: Immunopathology. In: Klippel JH, Dieppe PA, eds. Rheumatology. 2nd edition. Mosby, Philadelphia. 1998.

  2. Grossman JM, Tsao BP. Genetics and Systemic Lupus Erythematosus. Current Rheumatology Reports 2000; 2: 13-18.

  3. Pisetsky D S. AntiDNA and autoantobodies. Curr Opin In Rheumatol 2000; 12: 364-368.

  4. Arnett FC. The genetics of human lupus. In Dubois' Lupus Erythematosus, ed 5 by Wallace DJ, Hahn BH. Baltimore: Williams & Wilkins; 1997; 77-117.

  5. Sobel ES, Mohan C, Morel L et al. Genetic dissection of SLE pathogenesis: adoptive transfer of Sle 1 mediates the loss of tolerance by bone marrow derived b cells. J Immunol 1999; 162: 2415-2421.

  6. Morel L, Wakeland EK: Susceptibility to lupus nephritis in the NZB/W model system. Curr Opin immunol 1998, 10: 718-725.

  7. Vyse TJ, Kotzin BL. Genetic Susceptibility to systemic lupus erithematosus. Annu Rev Immunol 1998; 16: 261-292.

  8. Thefilopoulos AN, Kono DH. The genes of systemic autoimmunity. Proc Assoc Am Phys 1999; 111: 228-240.

  9. Tsao BO, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erithematosus. J Clin Invet 1997; 99: 725-731.

  10. Schwartz RS, Ayollar BD. Origins of anti-DNA autoantibodies. J Clin Invest 1985; 75: 321-327.

  11. Satoh M, Kumar A, Kanwar YS, Reeves WH. Anti-nuclear antibody production and immune _complex glomerulonephritis in BALB/c mice treated with pristine. Proc Natl Acad Sci U S A 1995; 92: 10934-10938.

  12. Desai DD, Krishnan MR, Swindle, JT, Marion TN. Antigen-specific induction of antibodies against native mammalian DNA in nonautoimmune mice. J Immunol 1993; 151: 1614-1626.

  13. Burlingame RW, Boey ML, Stakerbaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erithematosus. J Clin Invest 1994; 94: 184-192.

  14. Lefkowith JB, Kiehl M, Rubenstein J, et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erithematosus. J Clin Invest 1996; 98: 1373-1380.

  15. Mohan C, Adams S, Stanik V, Datta SK. Nucleoside: a major immunogen for pathogenic autoantibody_inducing T cells of lupus. J Exp Med 1993; 177: 1367-1381.

  16. Amoura Z, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Curr Opin Rheumatol 2000; 12: 369-373.

  17. Jmaes JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B' derived PPPGMRPP and PPPGIRGP induce splaiceosome autoimmunity. J Exp Med 1995; 181: 453-461.

  18. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erithematosus. J Immunol 1994; 152: 3685-3692.

  19. Lorenz H-M, Grunke M, Hieronymus T, et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic erithematosus and other autoimmune diseases. Arthritis Rheum 1997; 40: 306-317.

  20. Hermann M, Voll RE, Zoller OM, et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erithematosus. Arthritis Rheum 1998; 41: 1241-1250.

  21. Lederach D, Bach JF, Koutouzov S. Nucleosomas inhibit phagocytosis of apoptotic thymocytos by peritoneal macrophages from MRL+/+ lupus prone mice. J Leukoc Biol 1998; 68: 774-780.

  22. Zahir A, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Current Opinion in Rheumatology 2000; 12: 369-373.

  23. Rekvig OP, Moens U, Sundsfjord A, et al. Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen: a molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. J Clin Invest 1997; 99: 2045-2054.

  24. Andreassen K, Moens U, Nossent H, et al. Termation of human T cell tolerance to histones by presentation of histones and polyomavirus T antigen providen that T antigen is complexed with nucleosomes. Arthritis Rheum 1999; 42: 2449-2460.

  25. Pisetsky DS, Jelinek DF, McAnally LM, Lipsky PE, et al. In vitro autoantibody production by normal adult and cord blood cells. J Clin Invest 1990; 85: 899-903.

  26. Diamond B, Katz JB, Paul E, Aranow C, Lustgarten D. The role of somatic mutation in the pathogenic anti-DNA response. Annu Rev Immonol 1992; 10: 731-757.

  27. Rothfield NF, Stollar BD. The relation of immunogobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967; 46: 1785-1794.

  28. Mohan C, Datta SK. Lupus key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol 1995; 77: 209-220.

  29. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1997; 59: 90-96.

  30. Hemmer B, Fleckenstein BT, Vergelli M, et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 1997; 185: 1651-1659.

  31. Kamradt TN. Advances in Immunology: Tolerance and autoimmunity. NEJM; 2001; 344: 655-664.

  32. Nemazee DA, Burki K. Clonal deletion of lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989; 337: 562-566.

  33. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnaow CC. Expansion or elimination of B cells in vivo: dual roles for CD40-and Fas (CD95)- ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319-329.

  34. Goodnow CC, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334: 676-682.

  35. Nemazee DA. Receptor selection in B and T lymphocytes. Annu Rev Immunol 2000; 18: 19-51.

  36. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16: 421-432.

  37. Haakenstad AO, Mannik M. Saturation of the reticuloendothelial system with soluble immune complexes. J Immunol 1974; 112: 1939-1947.

  38. Davies Ka, Peters AM, Beynon HLC, Walport MJ. Immune complex processing in patients with sytemic lupus erythematosus. J Clin Invest 1992; 90: 2075-2083.

  39. Suzuky N, Harada T, Mizushima Y, Sakane T. Possible pathogenic role of cationic anti DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus: J Immunol 1993; 151: 1128-1136.

  40. Kimberly R. Immune complexes in the rheumatic diseases. Rheumatic diseases clinics of north America 1987; 13: 583-596.

  41. Cornacoff JB, Hebert LA, Smead WL, VanAmman ME, Birmingham DJ, Waxman FJ > Primate erythrocyte-immune complex clearing mechanism. J Clin Invest 1983; 71: 236-247.

  42. Wilson JG, Fearon DT. Altered expression of complement receptors as a pathogenic factor in systemic lupus erythematosus. Arthritis Rheum 1984; 27: 1321.

  43. Schifferli JA, Ng YC, Peters DK. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986; 315: 488.

  44. Salmon JE, Millard S, Schachter LA, Arnet F, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson M, Kimberly R. FcgRIIA alleles are heritable risk factors for lupu snephritis in African-Americans. J Clin Invest 1996; 97: 1348-1354.

  45. Wener MH, Mannik M, Schwartz MM, et al. Relationship between renal pathology and the size of circulating immune complexes in patients with systemic lupus erythematosus. Medicine 1987; 66: 85.

  46. Augener W, Grey HM, Cooper NR, et al. The reaction of monomeric and aggregated immunoglobulins with C1. Int J Immunochem 1971; 8: 1011.

  47. Clark MR, Stuart SG, Kimberly RP, Ory PA, and Goldstein IM. A single amino acid distinguishes the high-responder from low-responder form of Fc receptor II on human monocytes. Eur J Immunol 1991; 21: 1911-1916.

  48. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcg receptor IIA and Fcg receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89: 1274-1278.

  49. Alarcon-Segovia D, Llorente L. Antibody penetration into living cells. IV. Different effects of anti-native DNA and anti-ribonucleoprotein IgG on the cell cycle of activated T gamma cells. Clin Exp Immunol 1983; 52: 365-371.

  50. Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP. Receptor-mediated cellular entry of nuclear localizing anti DNA antibody via myosin 1. J Clin Invest 1997; 100: 25-31.

  51. Brinkman K, Termaat R, Berden Berden JH, Smeenk RJ. Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immonol Today 1990; 11: 232-234.

 

 Haga su consulta por tema

Búsqueda personalizada